Anixa says Phase 1 breast cancer vaccine trial meets endpoints, Phase 2 preparations underway
Reuters2026/08/24 12:55- Anixa Biosciences will present clinical updates at the Cantor Fitzgerald Global Healthcare Conference on Sept. 11, 2026.
- Final Phase 1 breast cancer vaccine results were already presented, showing the study met its main goals, supporting Phase 2 planning.
- Ovarian cancer CAR-T program lira-cel has moved to the highest dose cohort, adding lymphodepletion, with no dose-limiting toxicities reported.
- Several treated patients have remained alive beyond one year, underpinning continued development in heavily pre-treated recurrent ovarian cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Data: Detected an outflow of 35.11 million USDT from a certain exchange
SK Hynix CEO: Memory chip shortage will persist until 2030
Crypto prices
More
